Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.

Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activator at the same time as reducing its associated complications related to hemorrhage and neurotoxicity. We believe that the combination of low-dose tissue plasminogen activator with recombinant annexin A2 (a tissue plasminogen activator and plasminogen coreceptor) might constitute a promising approach. Our pilot study using a focal embolic stroke model in rats supports this hypothesis.
AuthorsXiang Fan, Zhanyang Yu, Jianxiang Liu, Ning Liu, Katherine A Hajjar, Karen L Furie, Eng H Lo, Xiaoying Wang
JournalStroke; a journal of cerebral circulation (Stroke) Vol. 41 Issue 10 Suppl Pg. S54-8 (Oct 2010) ISSN: 1524-4628 [Electronic] United States
PMID20876506 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Annexin A2
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
  • Animals
  • Annexin A2 (therapeutic use)
  • Brain Ischemia (drug therapy)
  • Drug Therapy, Combination
  • Fibrinolytic Agents (therapeutic use)
  • Pilot Projects
  • Rats
  • Stroke (drug therapy)
  • Thrombolytic Therapy (methods)
  • Tissue Plasminogen Activator (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: